Twist Bioscience Corp (TWST) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$158.44

From 52W high+0.00%

Volume3.05M

Market cap$11.07B

P/E (TTM)—

P/S (TTM)25.6x

Div yield—

Key dataSep 18, 2026

Open

$158.44

From 52W high

+0.00%

Volume

3.05M

Market cap

$11.07B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−102.0x

P/E (TTM)

—

RSI (14)

71.3

MomentumView details →

1D Return

+7.35%

YTD Return

+412.19%

SummaryUpdated Jun 1, 2026

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company founded in 2013 and headquartered in South San Francisco, California. The company went public in October 2018 and has established itself as a leader in DNA synthesis technology. Twist operates a proprietary silicon-based DNA synthesis platform that enables the manufacturing of synthetic DNA by literally "writing" DNA sequences on silicon chips, similar to how computer chips are manufactured. The company has grown from a startup to serving over 3,500 customers globally across academic, biotechnology, pharmaceutical, and industrial markets.

Ask drillr about Twist Bioscience Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−102.0x

EV/Sales

25.5x

P/S (TTM)

25.6x

P/B (TTM)

24.8x

ProfitabilityView details →

Gross Margin

51.97%

Net Margin

−31.66%

EBITDA Margin

−24.96%

ROE (TTM)

−30.67%

ROA (TTM)

−20.33%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

+19.19%

EPS YoY

−53.10%

FCF YoY

−35.52%

Revenue CAGR 3Y

+22.76%

EPS CAGR 3Y

+63.89%

EBITDA YoY

−81.51%

MomentumView details →

1D Return

+7.35%

YTD Return

+412.19%

1Y Return

+482.53%

RSI (14)

71.3

vs 50D SMA

+36.50%

vs 200D SMA

+131.65%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

2.67x

Quick Ratio

2.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

−10.62%

Beats (12Q)

8/12

Next Q EPS Est

−$0.39

Avg Surprise (4Q)

−7.83%

Rev Surprise

3.37%

Financials snapshotView financials →

Revenue (TTM)

431.80M

Net Income (TTM)

−136.72M

Op. CF (TTM)

−53.07M

Next earningsNov 13, 2026 →

Latest newsMore news →

Twist Bioscience stock rose more than 31% over the week following its Lilly TuneLab announcement.2d ago

Twist Bioscience Corporation announced an agreement with Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform.4d ago

Similar companies

ICON Public Limited CompanyICLR Charles River Laboratories International, Inc.CRL Qiagen N.V.QGEN 金域医学603882.SH Revvity, Inc.RVTY Medpace Holdings, Inc.MEDP Find similar companies →

Latest newsMore news →

Twist Bioscience stock rose more than 31% over the week following its Lilly TuneLab announcement.2d ago Twist Bioscience Corporation announced an agreement with Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform.4d ago Brandywine Managers LLC acquired a new position in Twist Bioscience Corporation, purchasing 20,970 shares valued at approximately $2.16 million during the second quarter, as disclosed in a Form 13F filing.26d ago